Difference between revisions of "Malignant solid neoplasm, SMO-mutated or PTCH-1-mutated (Hedgehog)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 50%; text-align:center;"" to "{| class="wikitable" style="width: 40%; text-align:center;"") Tags: mobile edit mobile web edit |
Warner-admin (talk | contribs) m (Text replacement - "|Phase II" to "|Phase 2") |
||
| Line 18: | Line 18: | ||
|- | |- | ||
|[https://doi.org/10.1200/JCO.2017.75.3780 Hainsworth et al. 2018 (MyPathway)] | |[https://doi.org/10.1200/JCO.2017.75.3780 Hainsworth et al. 2018 (MyPathway)] | ||
| − | |style="background-color:#91cf61"|Phase | + | |style="background-color:#91cf61"|Phase 2a |
|- | |- | ||
|} | |} | ||
Revision as of 17:38, 12 February 2022
1 regimens on this page
1 variants on this page
|
All lines of therapy
Vismodegib monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Hainsworth et al. 2018 (MyPathway) | Phase 2a |
Eligibility criteria
- SMO p.W535L or other nonsynonymous mutations, or PTCH-1 loss-of-function mutations
Targeted therapy
- Vismodegib (Erivedge) 150 mg PO once per day
Continued indefinitely
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed